Friday's stocks to watch: DDR, HES, VSTM >>> READ MORE

Deleterious Earnings Momentum Drop GlaxoSmithKline (GSK) to Sell

GSK stock a sell in latest weekly rating.

By Portfolio Grader

GlaxoSmithKline Plc (NYSE:GSK) is a $88.4 billion in market value constituent of the Pharmaceuticals GICS industry group where The current Portfolio Grader ranking for GSK puts it 77 among the 133 companies in this industry group, giving it a below-average spot. GSK is ranked in the third quartile of the sector with a ranking of 499 among the 785 companies in the sector and number 3,205 in the 5000 company Portfolio Grader company universe.

GSK is rated as a Sell using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

The Health Care sector is ranked number 10 among the 12 sectors in the Portfolio Grader universe putting it in the bottom quartile of all the GICS sectors. The Pharmaceuticals industry group is ranked 53 among the 69 industry groups within the GICS sectors, placing it well below-average in terms of the Navellier scoring system.

The company scores are below-average in 4 of the 8 areas evaluated by Portfolio Grader in the ranking of company stocks.

GSK's operational scores provide mixed results with rankings for operating margin and earnings growth that are well above average, while the score for sales growth is below average. Scores for visibility of earnings are worse than the industry norms for earnings revisions, earnings surprises, and earnings momentum. GSK's scores for return on equity and cash flow are discernibly better than its industry group average. GlaxoSmithKline's fundamental scores give GSK a place in the top quartile of the industry group.

The Navellier Proprietary Quantitative Score is used by Portfolio Grader to gauge GSK's shares from the angle of risk/reward. This unique scoring system takes into account the relative value of GSK's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Considering this risk/reward calculation, the company currently scores below-average in its industry group compared to its peers.

Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'. Explore the tool here.

Commentary provided by UpTick Data Technologies.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC